Reinforcements in SpectraCure’s organization

Today we are welcoming Johan Glindre to SpectraCure. Johan Glindre will be working as a Clinical Project Leader and has a solid background in clinical studies, project management and quality work. Johan holds a Master of Molecular Biology from Lund University, and has among other things, been working for Pharmacia and OctaPharma with quality work in laboratory and method development. In recent years he has lead projects and coordinated human clinical studies as well as preclinical studies on animals, at CanImGuide.

– I am very much looking forward to participating in SpectraCure's clinical studies and projects going forward, as well as building contacts with clinics and setting up networks, says Johan Glindre.

– It feels great to strengthen the competence within the company with a Clinical Project Leader who will, among other things, work on developing our already established contacts in the clinical studies, but also on developing new contacts, says Johannes Swartling, CTO SpectraCure.

Annika Andersson, SpectraCure’s Communication Manager since September 1st, 2019, is now part of the company’s management team.

– It is natural that Annika is part of the management team. Communication is an important component of the connection between vision, decision, leadership and executive. She has the communication skills and experience required and contributes with a communicative perspective in our joint work, internally as well as externally, says Masoud Khayyami, CEO SpectraCure.

– During autumn, I immersed myself in the functions of the business to be able to participate in discussions and to create strategies and structures for communication and marketing. This work is ongoing, and I am glad to contribute to drive SpectraCure forward together with the rest of the management team, says Annika Andersson.


For further information, please contact:

Masoud Khayyami, CEO SpectraCure AB publ.

Johannes Swartling, CTO SpectraCure

Annika Andersson, CCO SpectraCure

Certified Adviser is G&W Fondkommission, e-mail:, phone: +46 8503 000 50.


SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as “Interstitial Photodynamic Therapy”, PDT, a treatment methodology suitable for internal solid tumors of various kind e.g. prostate and abdominal glands, but also other indications such as cancer tumors in the head and neck region.